Investigating a protein that helps control cell division and its role in cancer and birth defects
Official title: The function and regulation of the C. elegans Haspin histone kinase homolog, HASP-1
Funded at University of Portland · NIH-10792737 · Data updated 2026-11-12
This study is looking at a protein called Haspin, which helps make sure our cells divide correctly, and it's for anyone interested in how new cancer treatments might work better by targeting this protein to kill cancer cells without hurting healthy ones.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Portland NIH-funded |
| Lab location | 1 site (Portland, United States) |
| Project start | September 22, 2023 |
| Project end | September 20, 2026 |
| Funding year | 2023 |
| Award (this year) | $408,521 |
| NIH project number | 1R15GM152945-01 |
| Project ID | NIH-10792737 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals with cancers or congenital abnormalities related to chromosome segregation errors.
✕Less likely to help
Patients with conditions unrelated to chromosome segregation or those not affected by cancer or congenital abnormalities may not benefit from this research.
What this research studies
This research focuses on understanding the function and regulation of a protein called Haspin, which plays a crucial role in how chromosomes are passed on during cell division. Errors in this process can lead to birth defects and cancer. The study aims to explore how Haspin can be targeted by new chemotherapy drugs that may effectively kill cancer cells while minimizing harm to normal cells. By studying Haspin's mechanisms, researchers hope to develop safer and more effective cancer treatments.
Why it matters
Potential benefit: If successful, this research could lead to the development of new cancer therapies that are less toxic to healthy cells.
How similar studies have gone: Previous research has shown promise in targeting similar proteins for cancer treatment, indicating a potential for success in this novel approach.
Where this research is happening
-
University of Portland
Portland, United States Active
Researchers
- Principal investigator: Wynne, David J — University of Portland
- Study coordinator: Wynne, David J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.